biotech / news / / The Hindu Business Line
Sanofi’s AccelRare tool helps whittle it down to the top five diagnosis of the child, in a matter of 10 minutes.
Sanofi India's AccelRare AI tool provides rare disease pre-diagnosis in just 10 minutes.
KEY POINTS
- AccelRare covers 310 rare diseases with an 88 percent diagnosis accuracy for healthcare practitioners.
- The tool was co-developed by 67 rare disease experts and validated across 13 disease networks.
- AccelRare requires no registration, collects no patient identification, and is free for users.
- AccelRare is approved as a Class A medical device in India and Class I in Europe.
COMPANIES
Summarized by Newsio from The Hindu Business Line. How we summarize →